Clinical trial
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic…
NCT00131313 · East Valley Hematology and Oncology Medical Group, Other · Unknown status
Key facts
| NCT number | NCT00131313 |
|---|---|
| Title | Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. |
| Official title | A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. |
| Lead sponsor | East Valley Hematology and Oncology Medical Group, Other |
| Collaborators | Mena, Raul, M.D. Pharmatech Oncology Industry Astex Pharmaceuticals, Inc. |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Nipent, Cytoxan, Rituxan |
| Enrollment | 180 |
| Start date | Jan 1, 2003 |
| Completion | Apr 1, 2009 |
| First posted | Aug 18, 2005 |
| Last update posted | Aug 18, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: